Skip to main content
Log in

ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark J. Truty MD, MS.

Ethics declarations

Disclosures

Thor Halfdanarson has the following disclosures: consulting/advisory board for Curium, Terumo, Advanced Accelerator Applications, Novartis, Crinetics, and ITM. He has received research support from Advanced Accelerator Applications, Novartis, Basilea, Agios, Turnstone Biologics, and Thermo Fisher Scientific.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alva-Ruiz, R., Yohanathan, L., Yonkus, J.A. et al. ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol 29, 1594–1595 (2022). https://doi.org/10.1245/s10434-021-11076-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-11076-w

Navigation